We have developed comprehensive resources and provide dedicated support to aid healthcare providers in incorporating the TruCheck test into their existing practices. The simplicity of the TruCheck test, which only necessitates a standard blood draw, makes it easy to integrate into existing patient interactions, such as routine check-ups or regular blood work.
The TruCheck test is advised for application in adults with an increased risk of cancer. It’s meant to complement, not replace, standard cancer screenings. TruCheck is not suggested for individuals who are below the age of 40, have cancer currently or have had treatment for any type of cancer previously.
The TruCheck test can be ordered through our online portal or by completing a paper request form.
We only need a single blood draw. Please refer to our Specimen Collection instructions. We can provide you with a phlebotomist.
Test results are typically available within 2 weeks. You will receive a notification when results are ready.
TruCheck test results will be dispatched to the healthcare provider who placed the order, approximately two weeks post the receipt of the patient’s sample at the laboratory. Healthcare providers can access these results through the Provider Portal. Users of the Provider Portal have the option to establish email notifications for alerting when new results are available.
A ‘Negative for Malignancy’ outcome from the TruCheck test implies that, within the test’s defined accuracy bounds, no Circulating Tumor Cells (CTCs) were discerned in the patient’s blood sample. This likely points to the absence of an active cancer that the test can identify at the time of testing. However, it’s crucial to bear in mind that TruCheck may not detect certain cancers. As such, a ‘negative’ result does not entirely eliminate the possibility of those specific cancers. Therefore, regular health evaluations and any cancer screenings advised by you as their healthcare provider continue to be of utmost importance.
A ‘Positive for Malignancy’ outcome from the TruCheck test indicates the detection of Circulating Tumor Cells (CTCs) in the patient’s blood sample, signifying the presence of cancer. Alongside this finding, the test provides an analytical assessment suggesting the probable organ of origin and the type of malignancy, aiming to accurately predict the organ potentially affected by the cancer. However, this is a screening test, not a definitive diagnostic tool. In the event of a ‘positive’ result, you should review the TruCheck report for your patient and advise on further steps, which may involve additional diagnostic tests. Only a healthcare professional can confirm a cancer diagnosis.
Please fill in the following form and we’ll get back to you. Our typical response time is 2 hours. You can also contact us at +44 20 8133 4424 or help@cancerscanuk.co.uk
The TruCheck test is suggested for use in adults with a higher risk of cancer, typically those aged 50 or above. TruCheck does not detect all types of cancers and should be considered a supplemental tool alongside routine cancer screening tests advised by your healthcare provider. The primary goal of TruCheck is to identify cancer signals and predict their origin within the body. It is not recommended for use in individuals who are pregnant, under the age of 40, or currently undergoing active cancer treatment.
Results must be analysed by a healthcare professional, taking into account the patient’s medical history, clinical signs, and symptoms. A result of “No Cancer Signal Detected” does not definitively exclude the presence of cancer. Likewise, a “Cancer Signal Detected” result necessitates further diagnostic evaluation through established medical procedures (such as imaging) to confirm the presence of cancer.
In cases where further testing does not confirm cancer, this could indicate either the absence of cancer or that the test was unable to detect it, including situations where the cancer is located in a different part of the body. Be aware that false-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) results can occur.
1. Akolkar et al. B15: Circulating tumor cells express tissue specific antigens in multiple cancers. Clin Cancer Res.2020;
26(11_Suppl). DOI: 10.1158/1557-3265.LiqBiop20-B15.
2. Akolkar et al. Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer. Int. J.
Cancer:2019; 146, 3485-3494. DOI: 10.1002/ijc.32815.
3. Gaya A et al. Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging. Cancer Cytopathol.
2020; 129 (3) 226-238 doi: 10.1002/cncy.22366.
4. Ranade A et al. Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk. Cancer
Prev Res. 2021;14:11-6 DOI:10.1158/1940-6207.CAPR-20-0322.
5. Crook T et al. Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. Cancers
(Basel). 2022 Jul; 14(14): 3341. DOI: 10.3390/cancers14143341.
